0001104659-26-057110
SEC filingIronwood achieved a dramatic profitability turnaround in Q1 2026, with revenue more than doubling to $106.5M from LINZESS U.S. profit share and prior restructuring benefits, delivering 68.1% operating margins despite non-cash tax impacts.
Ironwood Pharmaceuticals delivered a strong Q1 2026 performance, marking a shift to profitability fueled by robust revenue growth and cost efficiencies from prior restructuring. Revenue climbed to $106.5M, a 158.9% increase from $41.1M in the prior-year quarter, primarily from net profits consisting of net sales to third-party customers and sublicense income in the U.S. This surge reflects the ongoing strength of the LINZESS collaboration with AbbVie, which continues to form a significant portion of total revenue.
Looking ahead, Ironwood expects substantial selling, general, and administrative expenses as it invests in LINZESS commercialization, apraglutide development, and other candidates. Revenues from AbbVie and other activities remain critical to sustaining positive cash flows, though timing uncertainties persist. Management emphasizes proactive capital structure management, considering financing opportunities to bolster long-term liquidity amid debt obligations and pipeline execution.